secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2024-05-20T23:59:59+00:00
Accession:  0000950170-24-062387
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA removes partial clinical hold on Larimar's nomlabofusp for Friedreich's Ataxia
--------------------------------------------------------------------------------

- FDA cleared Phase 2 data review; nomlabofusp generally well-tolerated with dose-dependent frataxin increases.
- OLE study continues at 25 mg; dose escalation to 50 mg planned after further frataxin PD characterization.
- Interim OLE data expected Q4 2024; BLA submission targeted for 2H 2025.
- In 50 mg cohort, all evaluable patients achieved skin frataxin >33% of healthy volunteer average at Day 14.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024062387/0000950170-24-062387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024062387/lrmr-20240520.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-062387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer